Inhibition of Schistosoma mansoni Thioredoxin-glutathione Reductase by Auranofin

  title={Inhibition of Schistosoma mansoni Thioredoxin-glutathione Reductase by Auranofin},
  author={Francesco Angelucci and Ahmed A. Sayed and David L. Williams and Giovanna Boumis and Maurizio Brunori and Daniela Dimastrogiovanni and Adriana Erica Miele and Frida Pauly and Andrea Bellelli},
  journal={The Journal of Biological Chemistry},
  pages={28977 - 28985}
Schistosomiasis is a parasitic disease affecting over 200 million people currently treated with one drug, praziquantel. A possible drug target is the seleno-protein thioredoxin-glutathione reductase (TGR), a key enzyme in the pathway of the parasite for detoxification of reactive oxygen species. The enzyme is a unique fusion of a glutaredoxin domain with a thioredoxin reductase domain, which contains a selenocysteine (Sec) as the penultimate amino acid. Auranofin (AF), a gold-containing… 

Figures and Tables from this paper

Mapping the Catalytic Cycle of Schistosoma mansoni Thioredoxin Glutathione Reductase by X-ray Crystallography*

This study dissects the catalytic cycle of Schistosoma mansoni TGR by structural and functional analysis of the U597C mutant and proposes the putative functionally relevant conformational change of the C terminus after the transfer of reducing equivalents from NADPH to the redox sites of the enzyme.

Investigations of the catalytic mechanism of thioredoxin glutathione reductase from Schistosoma mansoni.

Variants of SmTGR were generated and it was suggested that reducing equivalents from NADPH can indeed reach the Cys-28/Cys-31 disulfide in the Grx domain to facilitate reductions effected by this cysteine pair, and selenocysteine is important but is not the sole determinant for the broad substrate tolerance of the enzyme.

The Enzymatic and Structural Basis for Inhibition of Echinococcus granulosus Thioredoxin Glutathione Reductase by Gold(I).

The structural study revealed that TGR functions are achieved not only through a mobile Sec-containing redox center but also by rotation of the Grx domain and distinct binding sites for thioredoxin and the glutaredoxin domain.

Structural and functional characterization of Schistosoma mansoni Thioredoxin

The high‐resolution crystal structure of Schistosoma mansoni Thioredoxin (SmTrx) is described, believing its crystal structure may provide clues for the formation of granulomas and the pathogenesis of the chronic disease.

Characterization of lead compounds targeting the selenoprotein thioredoxin glutathione reductase for treatment of schistosomiasis.

This effort has identified several active compound series that may serve as the basis for the development of new schistosomicidal compounds.

Cheminformatics Models for Inhibitors of Schistosoma mansoni Thioredoxin Glutathione Reductase

It is shown that a combined approach of machine learning and other cheminformatics approaches such as substructure comparison and molecular docking is efficient to prioritise molecules from large molecular datasets.

Thioredoxin Glutathione Reductase as a Novel Drug Target: Evidence from Schistosoma japonicum

This study confirms that a multifunctional enzyme SjTGR selenoprotein, instead of separate TrxR and GR enzymes, exists in S. japonicum and indicates that TGR may be a potential target for development of novel agents against schistosomes.

New drug target in protozoan parasites: the role of thioredoxin reductase

Evidence suggests that auranofin has the potential to become a broad spectrum alternative therapeutic agent for diseases with a large global burden of amebiasis.



Thioredoxin Glutathione Reductase from Schistosoma mansoni: An Essential Parasite Enzyme and a Key Drug Target

Investigating the potential of a unique, selenium-containing parasite enzyme thioredoxin glutathione reductase (TGR) as a drug target indicates that parasite TGR meets all the major criteria to be a key target for antischistosomal chemotherapy.

Glutathione reductase and thioredoxin reductase at the crossroad: The structure of Schistosoma mansoni thioredoxin glutathione reductase

The crystal structure of TGR from Schistosoma mansoni is reported, deleted in the last two residues, and the peculiar architecture of this chimeric enzyme is revealed, updating the interpretation of the interdomain communication in TGR enzymes.

Quantitative High-Throughput Screen Identifies Inhibitors of the Schistosoma mansoni Redox Cascade

This is, to the authors' knowledge, the first report of a large-scale HTS to identify lead compounds for a helminthic disease, and provides a paradigm that can be used to jump-start development of novel therapeutics for other neglected tropical diseases.

Identification of oxadiazoles as new drug leads for the control of schistosomiasis

Treatment of schistosome-infected mice with 4-phenyl-1,2,5-oxadiazole-3-carbonitrile-2-oxide led to marked reductions in worm burdens from treatments against multiple parasite stages and egg-associated pathologies, and protective effects exceed benchmark activity criteria set by the World Health Organization for lead compound development forschistosomiasis.

Thioredoxin reductase as a pathophysiological factor and drug target.

The hypothesis that TrxR and extracellular thioredoxin play a pathophysiologic role in chronic diseases such as rheumatoid arthritis, Sjögren's syndrom, AIDS, and certain malignancies, is substantiated by biochemical, virological, and clinical evidence.

The anti-schistosomal drug praziquantel is an adenosine antagonist

A hitherto unknown effect of PZQ is reported, namely the inhibition of nucleoside uptake, as observed in living worms using radio-isotope labelled adenosine and uridine, and this effect acquires significance given that schistosomes cannot synthesize purine nucleosides de novo.

Human Placenta Thioredoxin Reductase

In its physiological, NADPH-reduced form, the enzyme is strongly inhibited by organic gold compounds that are widely used in the treatment of rheumatoid arthritis; for auranofin, the K i was 4 nm when measured in the presence of 50 μmthioredoxin.